The effect of Empagliflozin on Glucagon, Beta hydroxybutyrate and insulin levels in type 2 diabetic patients

Not Applicable

Recruiting

• Conditions: Type 2 diabetes mellitus.; Type 2 diabetes mellitus

• Registration Number: IRCT20210730052022N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 November 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Type 2 diabetic patients
Thirty year old or more
Uncontrolled blood sugar after at least 3 months treatment with Metformin

Exclusion Criteria

Pregnant and lactating women
Renal failure (Glomerular Filtration Rate (GFR) less than 45 milliliters per minute)
Previous history of diabetic ketoacidosis (DKA)
Previous history of amputation due to diabetes
Consumption of drugs that affect the parameters of study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum level of Beta hydroxybutyrate. Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: Colorimetric assay using Randox kit with autoanalyzer.;Serum level of Glucagon. Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: Enzyme Linked Immunosorbent Assay (ELISA) method.;Serum level of Cortisol. Timepoint: Before strarting and then one month after treatment with Empagliflozin. Method of measurement: Radioimmunoassay (RIA) method.;Serum level of Insulin. Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: Radioimmunoassay (RIA) method.

Secondary Outcome Measures

Name	Time	Method
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). Timepoint: Before and then one month after treatment with Empagliflozin. Method of measurement: Calculation using blood sugar and Insulin levels in fasting state.;Weight. Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: Scale.;Body Mass Index (BMI). Timepoint: Before starting and then after one month treatment with Empagliflozin. Method of measurement: Calculation using weight and height.;Fasting Blood Sugar (FBS). Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: Colorimetric method with autoanalyzer.;Blood pressure. Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: Sphygmomanometer.;Glycated Hemoglobin (HbA1c). Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: High-Perforrmance Liquid Chromatography (HPLC).